Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Wall Street Transcript ,The
$50.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Innovus Pharmaceuticals Inc receives product license approval of EjectDelay for premature ejaculation from Health Canada


Friday, 6 Dec 2013 10:00am EST 

Innovus Pharmaceuticals Inc:Says it has received the approval of its product license for its over the counter (OTC) benzocaine-based topical premature ejaculation treatment EjectDelay in Canada.Says EjectDelay is an over-the-counter U.S. Food and Drug Administration and Health Canada compliant proprietary topical treatment containing the drug benzocaine and indicated for delay of premature ejaculation.Says the drug works within minutes of application to the glans of the penis. In clinical trials, the application of benzocaine has been shown to delay premature ejaculation by several minutes. 

Company Quote

0.27
-0.02 -5.26%
21 Nov 2014